Skip to main content
. 2013 Apr;29(3):290–297. doi: 10.1089/jop.2012.0235

Table 2.

Demographic and Baseline Characteristics

Demographic/baseline characteristics Total population N=679 BBFC N=218 Brinzolamide N=229 Brimonidine N=232
Age, years
 Mean±standard deviation 64.9±10.4 65.7±10.3 64.2±10.3 64.9±10.5
 <65, n (%) 323 (47.6%) 98 (45.0%) 110 (48.0%) 115 (49.6%)
 ≥65, n (%) 356 (52.4%) 120 (55.0%) 119 (52.0%) 117 (50.4%)
Race, n (%)
 White 529 (77.9%) 174 (79.8%) 179 (78.2%) 176 (75.9%)
 Black 130 (19.1%) 36 (16.5%) 42 (18.3%) 52 (22.4%)
 Asian 9 (1.3%) 3 (1.4%) 5 (2.2%) 1 (0.4%)
 Multi-racial 3 (0.4%) 0 (0%) 1 (0.4%) 2 (0.9%)
 Other 8 (1.2%) 5 (2.3%) 2 (0.9%) 1 (0.4%)
Sex, n (%)
 Male 298 (43.9%) 100 (45.9%) 97 (42.4%) 101 (43.5%)
 Female 381 (56.1%) 118 (54.1%) 132 (57.6%) 131 (56.5%)
Diagnosis, n (%)
 Ocular hypertension 168 (24.7%) 51 (23.4%) 59 (25.8%) 58 (25.0%)
 Open-angle glaucoma 511 (75.3%) 167 (76.6%) 170 (74.2%) 174 (75.0%)

Demographics and baseline characteristics were presented from the intent-to-treat population.

Intraocular pressure was analyzed using the intent-to-treat population.

BBFC, brinzolamide 1%/brimonidine 0.2% fixed combination.